TrialCardiovascular diabetology2020
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Ayako Fuchigami et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
46 papers cite it
this paperpooled ittrialcites it